Despite the POLARIX trial showing greater benefit for Pola-R-CHP in non-GCB DLBCL, experts don't use this biomarker for treatment decisions. The community's IHC-based testing is considered too discordant with the trial's GEP method to be clinically reliable.

Given that PD-L1 scores for gastroesophageal cancers can be exceptionally variable between labs, some clinicians prefer a simple CPS cutoff of 1. This 'some expression versus no expression' approach is considered more reproducible and practical for decision-making than relying on specific higher scores that may not be consistent across different testing sites.

The traditional "germinal center" (GC) classification for DLBCL is overly simplistic. Molecular analysis reveals distinct subtypes within GC, such as "dark zone" and "light zone" signatures, which have different prognoses and responses to targeted therapies like polatuzumab.

When considering escalating therapy for a patient with a high-risk p53 mutation, clinicians are adopting a key checkpoint: confirming the absence of a concurrent POLE mutation. The presence of a POLE mutation is thought to mitigate the aggressiveness of p53-mutated tumors, potentially making treatment escalation unnecessary.

Experts view R-mini-CHOP, the standard for older/unfit DLBCL patients, as a poor benchmark that urgently needs to be replaced. Promising chemo-free or chemo-light regimens, like the R-Polo-Glofitamab combination, are seen as the future, aiming to improve outcomes in this vulnerable population without harsh toxicities.

The traditional ABC/GCB classification for DLBCL is flawed. Single-cell sequencing reveals that tumors classified as one type via bulk analysis contain malignant cells of the other subtype. This underlying heterogeneity explains why the distinction is an imperfect predictor and will be replaced by more sophisticated biomarkers like T-cell exhaustion signatures.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

While clinicians often ponder how to prioritize treatments for patients with multiple actionable biomarkers, this scenario is exceedingly rare in practice. The guiding principle, if it does occur, is to choose the therapy with the strongest supporting clinical trial data, though this remains an infrequent dilemma.

The RSClin tool integrates a patient's Oncotype DX score with their unique clinical-pathologic features, such as tumor size and grade. This provides a more accurate and personalized risk assessment, as the same genomic score can represent significantly different prognoses for patients who have low versus high clinical risk factors.